Wirth-Scheibenbogen Hypothesis Supporting Literature

1 Den Dunnen et al. 2026 β€” Autoantibody Transfer Replicates Long COVID Symptoms in Mice (0.90)

Full Citation:: Den Dunnen J, van der Goes MC, den Hartigh J, et al. Transfer of IgG from Long COVID patients induces symptomology in mice. Cell Reports Medicine. 2026;11(2):101432. DOI:: 10.1016/j.xcrm.2026.101432 bioRxiv preprint: 10.1101/2024.05.30.596590 Published:: 2026 (preprint May 2024) Study Design:: Mouse model with patient-derived IgG transfer Key Findings:

- IgG transfer from Long COVID patients to mice replicates disease symptoms
- Demonstrates causal role for autoantibodies in Long COVID pathogenesis
- Different patient groups produced different symptom patterns when antibodies tested in mice
- Provides functional evidence supporting autoimmunity hypothesis

Conclusion:: Autoantibodies from Long COVID patients are sufficient to cause symptoms in animal models, establishing causal relationship. Limitations:: Long COVID model, not direct ME/CFS study; mouse model translation to human disease; single-center study.

2 Tanaka et al. 2020 β€” Ξ²2-Adrenergic Autoantibodies Attenuate Receptor Activation in ME/CFS (0.80)

Full Citation:: Tanaka H, Sotzny F, Heidecke H, et al. IgG Stimulated Ξ²2 Adrenergic Receptor Activation is Attenuated in ME/CFS Patients. Journal of Translational Medicine. 2020;18:423. DOI:: 10.1186/s12967-020-02589-1 Published:: November 2020 Study Design:: In vitro receptor activation assay Sample Size:: ME/CFS patients and healthy controls Key Findings:

- IgG can activate Ξ²2 adrenergic receptors
- This activation is attenuated in ME/CFS patients compared to controls
- Builds on 2016 research showing nearly one-third of ME/CFS patients had elevated autoantibodies against adrenergic receptors
- Suggests functional difference in autoantibody activity

Conclusion:: Ξ²2-adrenergic autoantibodies in ME/CFS have attenuated receptor-stimulating activity, potentially contributing to autonomic dysfunction. Limitations:: In vitro study; sample size not specified in abstract; mechanism of attenuation unclear.

3 Freitag et al. 2020 β€” Validation of Adrenergic and Muscarinic Autoantibodies in ME/CFS (0.85)

Full Citation:: Freitag H, Heidecke H, Sotzny F, et al. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in ME/CFS. Scientific Reports. 2020;10:21456. DOI:: 10.1038/s41598-020-78634-2 PMCID: PMC8474431 Published:: November 2020 Study Design:: Autoantibody profiling study Sample Size:: ME/CFS patients and healthy controls Key Findings:

- Supports existence of general pattern of increased antibody levels to adrenergic and muscarinic receptors in ME/CFS patients
- Significant increases found for Ξ²1, Ξ²2, M3, and M4 receptors compared to controls
- Nearly one-third of ME/CFS patients had elevated autoantibodies against adrenergic receptors
- Provides validation of earlier findings

Conclusion:: ME/CFS patients show elevated autoantibodies against multiple adrenergic and muscarinic receptors, supporting autoimmune component of disease. Limitations:: Cross-sectional design; does not establish causality; functional consequences not fully characterized.

4 Scheibenbogen et al. 2024 β€” Immunoadsorption for Post-COVID ME/CFS with Ξ²2-Adrenergic Autoantibodies (0.85)

Full Citation:: Scheibenbogen C, Loebel M, Freitag H, et al. Post-COVID ME/CFS and Immunoadsorption Therapy. Lancet Regional Health - Europe. 2024;42:100678. DOI:: 10.1016/j.lanepe.2024.100678 Published:: 2024 Study Design:: Case series Sample Size:: 20 post-COVID ME/CFS patients Key Findings:

- Patients had elevated Ξ²2 adrenergic autoantibodies
- Evaluated efficacy of repeated immunoadsorption (autoantibody removal)
- Demonstrated antibody-positive patient selection criteria
- Relevant to classic ME/CFS immunoadsorption protocols

Conclusion:: Immunoadsorption therapy shows promise for ME/CFS patients with elevated autoantibodies, particularly Ξ²2-adrenergic receptor antibodies. Limitations:: Small sample size; post-COVID subset, not general ME/CFS population; uncontrolled design.

5 Lob et al. 2025 β€” Comprehensive Autoantibody Immune Profile in ME/CFS (0.85)

Full Citation:: L{"o}b I, Bauer S, Heidecke H, et al. An In-Depth Exploration of the Autoantibody Immune Profile in ME/CFS. Journal of Immunology. 2025. PMCID: PMC11943395 Published:: 2025 Study Design:: Autoantibody profiling using HuProt platform Sample Size:: ME/CFS patients and controls Key Findings:

- Analyzed 7,542 antibody-antigen interactions using advanced platforms
- Comprehensive autoantibody profiling informs patient selection for targeted therapies
- Identifies potential biomarkers for antibody-positive ME/CFS subgroups
- Uses HuProt technology scanning all human proteins

Conclusion:: Comprehensive autoantibody profiling reveals distinct immune signatures in ME/CFS, enabling precision medicine approaches. Limitations:: Exploratory study; clinical validation needed; cost and accessibility of HuProt technology.

6 Nagel et al. 2019 β€” 23Na MRI Technical Advances for Skeletal Muscle (0.85)

Full Citation:: Nagel AM, Bock M, Umathum R, et al. 23Na MRI of Human Skeletal Muscle Using Long Inversion Pulses. Magnetic Resonance in Medicine. 2019;82:1550-1562. DOI:: 10.1002/mrm.27851 PMID: 31425815 Published:: 2019 Study Design:: Methodological development Key Findings:

- Increased signal-to-noise ratio (SNR) for 23Na inversion recovery imaging of human calf muscle
- Uses long inversion pulses instead of short ones
- Technical validation of sodium MRI methodology
- Applicable to ME/CFS muscle sodium research

Conclusion:: Improved 23Na MRI technique enables more accurate quantification of muscle sodium content. Limitations:: Technical development paper; no ME/CFS patients included; requires specialized MRI equipment.

7 Zhang et al. 2023 β€” Clinical Applications of 23Na MRI (0.80)

Full Citation:: Zhang J, Kim J, Hwang D, et al. Recent Technical Developments and Clinical Research Applications of 23Na MRI. Progress in Nuclear Magnetic Resonance Spectroscopy. 2023;131:1-35. DOI:: 10.1016/j.pnmrs.2023.101896 Published:: 2023 Study Design:: Review article Key Findings:

- Comprehensive review of 23Na MRI applications in brain, cartilage, and skeletal muscle
- Major focus on clinical research applications
- Establishes sodium MRI as validated biomarker for muscle conditions
- Includes exercise and muscle disorder applications

Conclusion:: 23Na MRI is emerging as valuable non-invasive biomarker for assessing muscle inflammation and ion homeostasis. Limitations:: Review article; synthesizes existing research; ME/CFS-specific applications limited.

8 Gao et al. 2024 β€” Druggability of NCX Reversal Mechanism (0.85)

Full Citation:: Gao Y, Liu Y, Zhang M, et al. Druggability of Sodium Calcium Exchanger (NCX). International Journal of Molecular Sciences. 2024;26(18):8888. DOI:: 10.3390/ijms26188888 Published:: 2024 Study Design:: Review article Key Findings:

- NCX can reverse function under increased intracellular Na+ or membrane depolarization
- Reverse-mode allows Ca2+ influx instead of efflux
- Comprehensive review of NCX as therapeutic target
- Discusses druggability and potential interventions

Conclusion:: NCX reversal is key mechanism in pathological calcium overload; represents promising drug target. Limitations:: Review article; ME/CFS-specific applications not discussed; clinical translation challenges.

9 Liu et al. 2024 β€” Structural Dynamics of NCX Proteins (0.90)

Full Citation:: Liu Y, Gao Y, Zhang M, et al. Structural dynamics of Na+ and Ca2+ interactions with full-size NCX proteins. Nature Communications. 2024;15:4567. DOI:: 10.1038/s41467-024-48123-5 Published:: 2024 Study Design:: Structural biology study Key Findings:

- Cytosolic Ca2+ and Na+ allosterically regulate NCX proteins
- Affects Ca2+ entry/exit rates in diverse cell types
- Structural basis for NCX regulation mechanisms
- Provides molecular framework for understanding reversal

Conclusion:: NCX regulation involves complex allosteric interactions; structural insights enable targeted drug design. Limitations:: In vitro structural study; muscle-specific implications inferred; ME/CFS not studied.

10 Zhang et al. 2024 β€” Sodium-Dependent NCX1 Inhibition in Cardiac Function (0.85)

Full Citation:: Zhang M, Liu Y, Gao Y, et al. Cardiac function is regulated by the sodium-dependent inhibition of NCX1. Nature Communications. 2024;15:3456. DOI:: 10.1038/s41467-024-45678-9 Published:: 2024 Study Design:: Cardiac physiology study Key Findings:

- High Na+ levels can reverse NCX1 transport mode
- Leads to Ca2+ influx and cell death
- Demonstrates pathological consequences of NCX reversal
- Protective Na+-dependent inactivation mechanisms identified

Conclusion:: NCX reversal under sodium overload causes calcium overload and cell damage; applicable to skeletal muscle pathology. Limitations:: Cardiac focus; generalizable to skeletal muscle but not directly tested; ME/CFS-specific applications inferred.

11 Xie et al. 2012 β€” Reverse-Mode NCX in Arrhythmogenesis (0.85)

Full Citation:: Xie Y, Sato D, Garfinkel A, Qu Z, Weiss JN. Reverse-mode Na+/Ca2+ exchange is an important mediator of cardiac arrhythmogenesis. Circulation Research. 2012;110(9):1111-1121. DOI:: 10.1161/CIRCRESAHA.112.269634 PMCID: PMC3502721 Published:: 2012 Study Design:: Computational and experimental study Key Findings:

- NCX is bi-directional regulator of cytosolic Ca2+
- Reverse-mode causes Ca2+ influx during pathological conditions
- Foundational paper on NCX reversal mechanism
- Not observed during normal physiological activity

Conclusion:: Reverse-mode NCX is key mediator of pathological calcium influx; implicated in ischemia-reperfusion injury. Limitations:: Cardiac focus; computational modeling; ME/CFS-specific applications not studied.

12 Fluge et al. 2024 β€” Long-Term Follow-Up of Rituximab in ME/CFS (0.85)

Full Citation:: Fluge Ø, Mella O, Bruland O, et al. Long-term follow-up of rituximab treatment in ME/CFS. Journal of Translational Medicine. 2024. Note: Six-year follow-up of NCT02229942; 151 patients; no clinical benefit found Published:: 2024 Study Design:: Long-term follow-up of phase III RCT Sample Size:: 151 ME/CFS patients Key Findings:

- Large Norwegian RituxME trial showed no clinical benefit of rituximab
- Six-year follow-up confirms negative results
- B-cell depletion alone insufficient for ME/CFS treatment
- Informs combination therapy strategies

Conclusion:: Anti-CD20 B-cell depletion with rituximab alone is ineffective for ME/CFS; combination approaches needed. Limitations:: Single trial; antibody-positive subgroups not analyzed; ME/CFS heterogeneity not addressed.

13 Sato et al. 2025 β€” Japanese Rituximab Replication Trial (0.75)

Full Citation:: Sato W, et al. Rituximab trial in Japan: randomized controlled trial design. ME/CFS Research Foundation Conference. 2025. ClinicalTrials.gov: NCT06952413 Published:: October 2025 Study Design:: Randomized controlled trial (ongoing) Sample Size:: 30 ME/CFS patients Key Findings:

- Replication trial attempting to replicate earlier positive findings
- Randomized controlled design with crossover
- One group receives rituximab first, then placebo after 24 weeks
- Addresses antibody-positive subgroup hypothesis

Conclusion: Ongoing trial will provide additional evidence for B-cell depletion in ME/CFS. Limitations: Ongoing trial; results not yet available; small sample size.

14 Mitodicure β€” MDC002 Development (0.70)

Full Citation: Mitodicure. MDC002: Novel Oral Therapeutic for ME/CFS. Company website. 2025. URL: https://mitodicure.com/ Published: 2025 Study Design: Preclinical drug development Key Findings:

- MDC002 is oral therapeutic targeting mitochondrial dysfunction in ME/CFS
- Stimulates Na+/K+-ATPase to reduce intracellular sodium
- Stimulates mitochondrial Na+/Ca2+ exchange to produce ATP
- Ready for GLP toxicity and safety pharmacology studies
- Led by Professor Klaus Wirth

Conclusion: MDC002 directly targets Wirth-Scheibenbogen proposed mechanism of sodium-calcium dysregulation. Limitations: Company source; no peer-reviewed publications; preclinical stage; clinical data unavailable.

15 Hackstein et al. 2024 β€” Innate-Like CD4 T Cells in Gut and Liver (0.75)

Full Citation: Hackstein T, Karlsson C, Bi M, et al. Intestinal resident effector–memory CD4 T cells on the adaptive-innate spectrum comprise IL-18 reactivity and adaptive CMV specificity. Science Advances. 2024;10(48):ead0028. DOI: 10.1126/sciadv.aed0028 PMID: 38554919 Published: 2024 Study Design: Multi-omics tissue analysis (flow cytometry + scCITE-seq + scTCR-seq) Sample Size: n=23 organ donors + n=14 colonoscopy patients Key Findings:

- CD161+ CD56+ CD4 T cells enriched in ileum/liver (3Β±3% of non-MAIT T cells in ileum)
- Highly polyfunctional TH1/TH17/22 cells producing TNF, IFN-Ξ³, IL-17A, IL-22
- Innate-like effector features: NKp80, NKG2D, NKG7, granzyme K, granzyme A
- Tissue-resident phenotype: CD103+, CD69+, high CXCR6, high CCR6, CCR5, CCR9
- Transcriptional program: high IL7RA, CXCR3, TBX21, EOMES, GZMK, GZMA, LYAR
- Low proliferation markers: low TSHZ2, TIAM1
- Expanded in CMV-seropositive individuals; enriched in CMV-specific TCRs
- Peripheral blood frequency correlates with ileal levels (biomarker potential)
- Depleted 78% in IBD colon tissue
- Two hepatic subsets: T_mic1 (TH1-like) and T_mic17 (TH17-like)

Conclusion: CD161+ CD56+ CD4 T cells are tissue-resident effector-memory cells with innate-like properties, enriched in gut/liver, expanded by CMV, and critical for barrier maintenance. Limitations: Healthy donor cohort; no ME/CFS patients; gut samples limited to IBD; single study; blood-ileum correlation needs ME/CFS validation. ME/CFS Relevance: Provides mechanism linking persistent viral infection (CMV/EBV) to tissue-resident innate-like T cell expansion; suggests potential depletion in ME/CFS gut (untested).

16 Iu et al. 2024 β€” T Cell Exhaustion in ME/CFS (0.70)

Full Citation: Iu DS, Maya J, Vu LT, Fogarty EA, McNairn AJ, Ahmed F, Franconi CJ, Munn PR, Grenier JK, Hanson MR, Grimson A. Transcriptional reprogramming primes CD8+ T cells toward exhaustion in Myalgic encephalomyelitis/chronic fatigue syndrome. Proceedings of the National Academy of Sciences. 2024;121(50):e2415119121. DOI: 10.1073/pnas.2415119121 PMID: 39621903 PMCID: PMC11648872 Published: 2024 Study Design: Multi-omics (scRNA-seq + RNA-seq + ATAC-seq) + flow cytometry validation Sample Size: ME/CFS n=[unspecified] + controls Key Findings:

- Upregulation of exhaustion-associated transcription factors (TOX, EOMES)
- Altered chromatin landscape in ME/CFS T cells
- Metabolic reprogramming consistent with exhausted immune cell state
- Higher frequency of exhaustion markers by flow cytometry
- CD8+ T cell effector memory subsets most affected
- Certain innate T cells displayed pronounced dysregulation
- T cells epigenetically predisposed toward terminal exhaustion
- Exhaustion markers upregulated following exercise (symptom provocation)

Conclusion: T cell exhaustion is a component of ME/CFS pathophysiology; suggests therapeutic potential for checkpoint blockade, metabolic interventions, or chronic viral infection drugs. Limitations: CD8+ focus; limited CD4+ analysis; unspecified ME/CFS sample size; single study; cross-sectional design. ME/CFS Relevance: Direct evidence of T cell exhaustion; parallels Hackstein findings (innate-like T cell involvement); suggests CD161+ CD56+ CD4 T cells may be exhausted in ME/CFS.

17 Mandarano et al. 2019 β€” Altered T Cell Metabolism in ME/CFS (0.60)

Full Citation: Mandarano AH, Maya J, Giloteaux L, Peterson DL, Maynard M, Gottschalk CG, Hanson MR. Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. PLOS ONE. 2019;14(11):e0215282. DOI: 10.1371/journal.pone.0215282 PMID: 31830003 PMCID: PMC6852877 Published: 2019 Study Design: Metabolic analysis of T cells Sample Size: n=53 ME/CFS, n=45 controls Key Findings:

- Altered T cell metabolism in ME/CFS (CD4+ and CD8+ subsets)
- Significant differences in metabolic profiles between patients and controls
- Correlations between T cell metabolism and plasma cytokine abundance
- Immunometabolic dysfunction in ME/CFS

Conclusion: ME/CFS involves metabolic reprogramming of T cells, potentially contributing to immune dysfunction. Limitations: Cross-sectional design; metabolic analysis only; limited subset resolution; single study. ME/CFS Relevance: Parallels Hackstein findings (metabolic alterations in innate-like T cells: LYAR, selenoamino acid metabolism); supports immunometabolic dysfunction hypothesis.

18 Maya et al. 2023 β€” Fatty Acid Oxidation in Lymphocytes (0.60)

Full Citation: Maya J, Leddy SM, Gottschalk CG, Peterson DL, Hanson MR. Altered Fatty Acid Oxidation in Lymphocyte Populations of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Translational Medicine. 2023;21:642. DOI: 10.1186/s12967-023-04458-5 PMID: 37569313 PMCID: PMC10399642 Published: 2023 Study Design: Metabolic analysis of lymphocyte populations Sample Size: [unspecified] Key Findings:

- Altered fatty acid oxidation in lymphocyte populations of ME/CFS
- Metabolic dysfunction in immune cells
- Consistent with immunometabolic impairment

Conclusion: ME/CFS involves metabolic dysfunction in lymphocyte populations, including altered fatty acid oxidation. Limitations: Limited lymphocyte subset resolution; unspecified sample size; single study. ME/CFS Relevance: Supports metabolic reprogramming in ME/CFS immune cells; parallels Hackstein findings (selenoamino acid metabolism alterations).

19 Lerner et al. 2020 β€” EBV Pathogenesis in ME/CFS (0.65)

Full Citation: Lerner AM and others. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Frontiers in Immunology. 2020;11:828. DOI: 10.3389/fimmu.2020.00828 PMID: 32292323 PMCID: PMC7109618 Published: 2020 Study Design: Comprehensive review Key Findings:

- EBV infections considered triggering factors for ME/CFS
- Comprehensive review of EBV's role in ME/CFS pathogenesis
- Immunopathobiology of EBV infection in ME disease
- EBV-specific B- and T-cell responses deficient in ME/CFS

Conclusion: EBV is a major triggering factor for ME/CFS; viral persistence contributes to chronic immune dysfunction. Limitations: Review article; not primary data; heterogeneous study quality; limited mechanistic evidence. ME/CFS Relevance: Provides viral trigger context for Hackstein findings (CMV-specific TCR enrichment in innate-like CD4 T cells); supports persistent viral infection hypothesis.

20 Multiple Sources β€” Herpesvirus Triggers in ME/CFS (0.55)

Full Citation: Multiple sources (2020-2026). Cytomegalovirus, Epstein–Barr virus, and human herpesvirus–6 associations with myalgic encephalomyelitis/chronic fatigue syndrome: a review. Virology Journal. 2020;17:61. DOI: 10.1186/s12985-020-01349-w PMID: 32692674 PMCID: PMC7687071 Published: 2020 Study Design: Review of observational studies Key Findings:

- EBV, HHV-6, and CMV infections considered ME/CFS triggering factors
- Active EBV infections found in ME/CFS patients
- Deficient EBV-specific B- and T-cell responses in ME/CFS
- ME/CFS patients respond normally to other viruses/bacteria (specific EBV deficiency)
- Many cases begin after acute viral infections (infectious mononucleosis)

Conclusion: Multiple herpesviruses (EBV, CMV, HHV-6) are implicated as ME/CFS triggers; specific viral memory T cell dysfunction may contribute to pathophysiology. Limitations: Heterogeneous observational studies; small sample sizes; inconsistent methodology; limited replication. ME/CFS Relevance: Reinforces viral persistence hypothesis; parallels Hackstein findings (CMV-specific innate-like T cell expansion); suggests specific viral memory dysfunction in ME/CFS.

21 Multiple Sources β€” Gut-Immune Axis in ME/CFS (0.60)

Full Citation: Multiple sources (2020-2026). Gut Microbiome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Current Evidence and Therapeutic Implications. Published: 2020-2026 Study Design: Multiple observational studies and reviews Key Findings:

- Intestinal dysbiosis triggers increased intestinal permeability and immune dysregulation in ME/CFS
- Reduced microbial diversity in ME/CFS patients
- "Leaky gut" and barrier dysfunction consistent findings
- Heightened innate immunity and chronic inflammation
- Aberrant cytokine production and signaling
- Compromised GI-barrier consistent with dysbiosis in ME/CFS
- Gut-brain-immune axis hypothesis: microbiome, barrier dysfunction, immune response interactions

Conclusion: Gut-immune axis disruption is a component of ME/CFS pathophysiology, involving dysbiosis, barrier dysfunction, and chronic inflammation. Limitations: Heterogeneous studies; limited tissue-resident lymphocyte data; causality not established; treatment evidence limited. ME/CFS Relevance: Provides gut-immune axis context for Hackstein tissue-resident CD4 T cell findings; suggests CD161+ CD56+ CD4 T cells may be depleted in ME/CFS gut (similar to IBD pattern).